Evaluation of single-dose RBC Pig-a and PIGRET assays in detecting the mutagenicity of thiotepa in rats

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 811, Issue , 2016, Pages 123-128

  Tsutsumi, Eri ^a   Momonami, Ayaka ^a   Hori, Hisako ^a   Kitagawa, Yoshinori ^a  

^a SUNTORY LTD   (Japan)

Author keywords

Gene mutation; Mutant frequency; PIGRET assay; RBC Pig a assay; Thiotepa

Indexed keywords

THIOTEPA; MEMBRANE PROTEIN; MUTAGENIC AGENT; PHOSPHATIDYLINOSITOL GLYCAN-CLASS A PROTEIN;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG SCREENING; ENZYME ASSAY; ERYTHROCYTE; GENE FREQUENCY; GENE MUTATION; IN VIVO STUDY; INFANT; MALE; MUTAGEN TESTING; MUTAGENICITY; MUTATION RATE; NONHUMAN; PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS A ASSAY; PIGRET ASSAY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; ANIMAL; BODY WEIGHT; DRUG EFFECTS; EVALUATION STUDY; GENETICS; PROCEDURES; RETICULOCYTE;

ANIMALS; BODY WEIGHT; ERYTHROCYTES; MALE; MEMBRANE PROTEINS; MUTAGENICITY TESTS; MUTAGENS; RATS; RATS, SPRAGUE-DAWLEY; RETICULOCYTES; THIOTEPA;

EID: 84979529715     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2016.06.002     Document Type: Article

References (32)

1. [1] Dobrovolsky, V.N., Miura, D., Heflich, R.H., Dertinger, S.D., The in vivo Pig-a gene mutation assay, a potential tool for regulatory safety assessment. Environ. Mol. Mutagen. 51 (2010), 825–835.
2. [2] Miura, D., Dobrovolsky, V.N., Kimoto, T., Kasahara, Y., Heflich, R.H., Accumulation and persistence of Pig-A mutant peripheral red blood cells following treatment of rats with single and split doses of N-ethyl-N-nitrosourea. Mutat. Res. 677 (2009), 86–92.
3. [3] Kawagoe, K., Takeda, J., Endo, Y., Kinoshita, T., Molecular cloning of murine pig-a, a gene for GPI-anchor biosynthesis, and demonstration of interspecies conservation of its structure function, and genetic locus. Genomics 23 (1994), 566–574.
4. [4] Miura, D., Dobrovolsky, V.N., Kasahara, Y., Katsuura, Y., Heflich, R.H., Development of an in vivo gene mutation assay using the endogenous Pig-A gene: I. Flow cytometric detection of CD59-negative peripheral red blood cells and CD48-negative spleen T-cells from the rat. Environ. Mol. Mutagen. 49 (2008), 614–621.
5. [5] Kimoto, T., Suzuki, K., Kobayashi, X.M., Dobrovolsky, V.N., Heflich, R.H., Miura, D., Kasahara, Y., Manifestation of Pig-a mutant bone marrow erythroids and peripheral blood erythrocytes in mice treated with N-ethyl-N-nitrosourea: direct sequencing of Pig-a cDNA from bone marrow cells negative for GPI-anchored protein expression. Mutat. Res. 723 (2011), 36–42.
6. [6] Itoh, S., Nagata, M., Hattori, C., Takasaki, W., In vivo mutagenicity of ethyl methanesulfonate detected by Pig-a and PIGRET assays. Genes Environ. 36 (2014), 174–178.
7. [7] Sanada, H., Okamoto, M., Ohsumi, T., Nakamura, T., Evaluation for a mutagenicity of 4,4'-methylenedianiline on hematopoietic cells by a Pig-a gene mutation assay in rats. Genes Environ. 36 (2014), 179–185.
8. [8] Muto, S., Yamada, K., Kato, T., Iwase, Y., Uno, Y., Pig-a gene mutation and micronucleus induction in rat peripheral blood by methyl methanesulfonate. Genes Environ. 36 (2014), 186–190.
9. [9] Kimoto, T., Chikura, S., Suzuki-Okada, K., Kobayashi, X., Itano, Y., Miura, D., Kasahara, Y., The rat Pig-a mutation assay in single and 28 day-repeated dose study of cyclophosphamide: the PIGRET assay can detect the in vivo mutagenicity earlier than the RBC Pig-a assay. Genes Environ. 36 (2014), 191–198.
10. [10] Horibata, K., Ukai, A., Honma, M., Evaluation of rats’ in vivo genotoxicity induced by N-ethyl-N-nitrosourea in the RBC Pig-a, PIGRET, and gpt assays. Genes Environ. 36 (2014), 199–202.
11. [11] Kimoto, T., Horibata, K., Chikura, S., Hashimoto, K., Itoh, S., Sanada, H., Muto, S., Uno, Y., Yamada, M., Honma, M., Interlaboratory trial of the rat Pig-a mutation assay using an erythroid marker HIS49 antibody. Mutat. Res. 755 (2013), 126–134.
12. [12] Ekhart, C., Kerst, J.M., Rodenhuis, S., Beijnen, J.H., Huitema, A.D., Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency. Cancer Chemother. Pharmacol. 63 (2009), 375–379.
13. [13] Ekhart, C., Rodenhuis, S., Beijnen, J.H., Huitema, A.D., Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen. Ther. Drug Monit. 31 (2009), 95–103.
14. [14] IARC, Thiotepa, in: Pharmaceutical Drugs, vol. 50, IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, Lyon, 1990, pp. 123–141.
15. [15] Maanen, M.J., Smeets, C.J., Beijnen, J.H., Chemistry pharmacology and pharmacokinetics of N,N',N''-triethylenethiophosphoramide (ThioTEPA). Cancer Treat. Rev. 26 (2000), 257–268.
16. [16] Kaldor, J.M., Day, N.E., Pettersson, F., Clarke, E.A., Pedersen, D., Mehnert, W., Bell, J., Høst, H., Prior, P., Karjalainen, S., Leukemia following chemotherapy for ovarian cancer. N. Engl. J. Med. 322 (1990), 1–6.
17. [17] IARC, Thiotepa, in: Pharmaceuticals, vol. 100A, IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, 2012, pp, 163–169.
18. [18] National Cancer Institute, Bioassay of Thiotepa for Possible Carcinogenicity, Technical Report Series No. 58, Washington DC: US Government Printing Office, No. DHEW Publication No. (NIH) (1978) 78–1308.
19. [19] Dertinger, S.D., Phonethepswath, S., Avlasevich, S.L., Torous, D.K., Mereness, J., Bryce, S.M., Bemis, J.C., Bell, S., Weller, P., Macgregor, J.T., Efficient monitoring of in vivo Pig-a gene mutation and chromosomal damage: summary of 7 published studies and results from 11 new reference compounds. Toxicol. Sci. 130 (2012), 328–348.
20. [20] Dertinger, S.D., Phonethepswath, S., Avlasevich, S.L., Torous, D.K., Mereness, J., Cottom, J., Bemis, J.C., Macgregor, J.T., Pig-a gene mutation and micronucleated reticulocyte induction in rats exposed to tumorigenic doses of the leukemogenic agents chlorambucil thiotepa, melphalan, and 1,3-propane sultone. Environ. Mol. Mutagen. 55 (2014), 299–308.
21. [21] Labash, C., Carlson, K., Avlasevich, S.L., Berg, A., Bemis, J.C., MacGregor, J.T., Dertinger, S.D., Induction of Pig-a mutant erythrocytes in male and female rats exposed to 1,3-propane sultone, ethyl carbamate, or thiotepa. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 782 (2015), 24–29.
22. [22] Kimoto, T., et al. The PIGRET assay, a method for measuring Pig-a gene mutation in reticulocytes, is reliable as a short-term in vivo genotoxicity test: summary of the MMS/JEMS-collaborative study across 16 laboratoriesusing 24 chemicals. Mutat. Res. 811 (2016), 3–15.
23. [23] Torabifard, H., Fattahi, A., Mechanisms and kinetics of thiotepa and tepa hydrolysis: DFT study. J. Mol. Model. 18 (2012), 3563–3576.
24. [24] Musser, S.M., Pan, S.S., Callery, P.S., Liquid chromatography-thermospray mass spectrometry of DNA adducts formed with mitomycin C, porfiromycin and thiotepa. J. Chromatogr. 474 (1989), 197–207.
25. [25] Hagen, B., Pharmacokinetics and pharmacodynamics of thioTEPA. Grochow, L.B., Ames, M.M., (eds.) A Clinician's Guide to Chemotherapy, Pharmacokinetics and Pharmacodynamics, 2016, Williams & Wilkins Baltimore, 1998, 427–433.
26. [26] Lyons, A.R., Edelstyn, G.A., Thiotepa in the treatment of advanced breast cancer. Br. J. Cancer 19 (1965), 490–495.
27. [27] Maier, P., Schmid, W., Ten model mutagens evaluated by the micronucleus test. Mutat. Res. 40 (1976), 325–337.
28. [28] Chen, T., Aidoo, A., Manjanatha, M.G., Mittelstaedt, R.A., Shelton, S.D., Lyn-Cook, L.E., Casciano, D.A., Heflich, R.H., Comparison of mutant frequencies and types of mutations induced by thiotepa in the endogenous Hprt gene and transgenic lacI gene of Big Blue rats. Mutat. Res. 403 (1998), 199–214.
29. [29] Chen, T., Aidoo, A., Mittelstaedt, R.A., Casciano, D.A., Heflich, R.H., Hprt mutant frequency and molecular analysis of Hprt mutations in Fischer 344 rats treated with thiotepa. Carcinogenesis 20 (1999), 269–277.
30. [30] Derelanko, M.J., Determination of erythrocyte life span in F-344, Wistar, and Sprague-Dawley rats using a modification of the [3H] diisopropylfluorophosphate ([3H] DFP) method. Fundam. Appl. Toxicol. 9 (1987), 271–276.
31. [31] Dertinger, S.D., Avlasevich, S.L., Torous, D.K., Bemis, J.C., Phonethepswath, S., Labash, C., Carlson, K., Mereness, J., Cottom, J., Palis, J., MacGregor, J.T., Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy. Toxicol. Sci. 140 (2014), 307–314.
32. [32] Gollapudi, B.B., Lynch, A.M., Heflich, R.H., Dertinger, S.D., Dobrovolsky, V.N., Froetschl, R., Horibata, K., Kenyon, M.O., Kimoto, T., Lovell, D.P., Stankowski, L.F. Jr., White, P.A., Witt, K.L., Tanir, J.Y., The in vivo Pig-a assay: a report of the international workshop on genotoxicity testing (IWGT) workgroup. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 783 (2015), 23–35.